Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2010

View Archived Issues

Preclinical data presented on Radius Health's SARM RAD-140

New class of toluidine sulfonamides set to enter clinical testing for the treatment of MM

New ligands of dopamine and/or serotonin 5-HT1A receptors reported

French scientists claim new cannabinoid CB2 receptor agonists

New inhibitors of HCV RNA-directed RNA polymerase claimed

Actelion discloses new agonists of formylpeptide FPR2/ALX receptors

Vertex modifies phase II trial of telaprevir plus VX-222 against hepatitis C

FBS-0701 is safe in phase Ib study in subjects with iron overload, phase II trial under way

Pan-5-HT1 receptor antagonist GSK-163090 progresses to clinical development

Potent analgesic activity seen with KD-7332 in vitro and in vivo

Novo Nordisk and Emisphere to develop oral insulin for diabetes

Applications for abiraterone acetate submitted to FDA and EMA

Oncothyreon begins phase I/II trial of PX-866/cetuximab combination

CHMP recommends approval of Teysuno for treatment of advanced gastric cancer

Ambit Biosciences begins phase I trials for AC-430 and AC-480

Chugai and Dainippon Sumitomo to conduct phase I/II trial of cancer vaccine WT-4869

CHMP recommends a variation to marketing terms for Simponi

CHMP recommends marketing authorization for Janssen-Cilag's Xeplion

Merck & Co. identifies new inhibitors of PDE10A

AstraZeneca discontinues motavizumab development for RSV

DSMB recommends continuation of phase II AX-200 efficacy trial

MAP Pharmaceuticals completes final trial for Levadex NDA submission

Isis begins phase I ISIS-APOCIIIRx trial to treat hypertriglyceridemia

Amarillo Biosciences to study oral interferon and Tamiflu for influenza

Amylin submits initial sections of rolling BLA for metreleptin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...